Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca appoints head of oncology

Dr Jamie Freedman joins from AZ subsidiary MedImmune

AZ Dr Jamie FreedmanAstraZeneca has appointed Dr Jamie Freedman as its new head of oncology, succeeding Dr Mondher Mahjoubi.

Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for leading AstraZeneca's biologics portfolio.

Prior to this, Dr Freedman served as GlaxoSmithKline's vice president of oncology R&D, and led OPKO Health's R&D department.

He also brings experience from biotech Locus Pharmaceuticals, where he was president, chief executive officer and chief medical officer, and Merck & Co, where he held several leadership roles in clinical pharmacology, oncology and experimental medicines.

12th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics